Myriad Genetics Inc. (MYGN)
Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President and Chief Executive Officer Sam Raha - Chief Operating Officer Mark Verratti - Chief Commercial Officer Scott Leffler - Chief Financial Officer Conference Call Participants Madeline Mollman - Wolfe Research Will Ortmayer - Goldman Sachs Madison Pasterchick - Morgan Stanley Tycho Peterson - Jefferies Sung Ji Nam - Scotia Bank Bill Bonello - Craig-Hallum Puneet Souda - Leerink Partners Ben Mee - Stephens Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call.
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
Myriad Genetics (MYGN) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago.
MYGN Stock Might Rise on Collaboration With CancerCARE
Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test.
MYGN Stock Gains Following the Launch of Know More Sooner
Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive and prenatal genetic testing.
MYGN Stock Gains Following Collaboration With Hannah Storm
Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador.
MYGN Stock Might Gain From the New Recognition of RiskScore Study
The American Journal of Human Genetics names Myriad Genetics' RiskScore study as one of the top 10 significant advances in genomic medicine.
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?
Myriad Genetics' Prolaris test reinforced as an 'Advanced Tool' by the NCCN for prognostic assessment.
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2
Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.
Myriad Genetics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Myriad Genetics, Inc. (MYGN)
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
